Blinklab Limited (AU:BB1) has released an update.
BlinkLab Limited is partnering with Bates College to conduct a clinical study on their new smartphone-based test for diagnosing Functional Neurological Disorder (FND), which is often misdiagnosed. The study will recruit up to 500 patients across Maine, New York, New Jersey, and other locations, with the aim of validating the BlinkLab Platform as an effective remote diagnostic tool over a three-year period. The research could lead to more accurate and accessible diagnostics for FND, potentially reducing the burden on patients and the healthcare system.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
